Feng Xie1,2, Kathryn Gaebel2, Kuhan Perampaladas1,2, Brett Doble1,2,3, Eleanor Pullenayegum1. 1. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada (FX, KP, BD, EP). 2. Programs for Assessment of Technologies in Health Research Institute, St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada (FX, KG, KP, BD) 3. Centre for Health Economics, Faculty of Business and Economics, Monash University, Clayton, Victoria, Australia (BD)
Abstract
BACKGROUND: There has been a growing interest around the world in developing country-specific scoring algorithms for the EQ-5D. This study systematically reviews all existing EQ-5D valuation studies to highlight their strengths and limitations, explores heterogeneity in observed utilities using meta-regression, and proposes a methodological checklist for reporting EQ-5D valuation studies. METHODS: . We searched Medline, EMBASE, the National Health Service Economic Evaluation Database (NHS EED) via Wiley's Cochrane Library, and Wiley's Health Economic Evaluation Database from inception through November 2012, as well as bibliographies of key papers and the EuroQol Plenary Meeting Proceedings from 1991 to 2012 for English-language reports of EQ-5D valuation studies. Two reviewers independently screened the titles and abstracts for relevance. Three reviewers performed data extraction and compared the characteristics and scoring algorithms developed in the included valuation studies. RESULTS: . Of the 31 studies included in the review, 19 used the time trade-off (TTO) technique, 10 used the visual analogue scale (VAS) technique, and 2 used both TTO and VAS. Most studies included respondents from the general population selected by random or quota sampling and used face-to-face interviews or postal surveys. Studies valued between 7 and 198 total states, with 1-23 states valued per respondent. Different model specifications have been proposed for scoring. Some sample or demographic factors, including gender, education, percentage urban population, and national health care expenditure, were associated with differences in observed utilities for moderate or severe health states. CONCLUSIONS: . EQ-5D valuation studies conducted to date have varied widely in their design and in the resulting scoring algorithms. Therefore, we propose the Checklist for Reporting Valuation Studies of the EQ-5D (CREATE) for those conducting valuation studies.
BACKGROUND: There has been a growing interest around the world in developing country-specific scoring algorithms for the EQ-5D. This study systematically reviews all existing EQ-5D valuation studies to highlight their strengths and limitations, explores heterogeneity in observed utilities using meta-regression, and proposes a methodological checklist for reporting EQ-5D valuation studies. METHODS: . We searched Medline, EMBASE, the National Health Service Economic Evaluation Database (NHS EED) via Wiley's Cochrane Library, and Wiley's Health Economic Evaluation Database from inception through November 2012, as well as bibliographies of key papers and the EuroQol Plenary Meeting Proceedings from 1991 to 2012 for English-language reports of EQ-5D valuation studies. Two reviewers independently screened the titles and abstracts for relevance. Three reviewers performed data extraction and compared the characteristics and scoring algorithms developed in the included valuation studies. RESULTS: . Of the 31 studies included in the review, 19 used the time trade-off (TTO) technique, 10 used the visual analogue scale (VAS) technique, and 2 used both TTO and VAS. Most studies included respondents from the general population selected by random or quota sampling and used face-to-face interviews or postal surveys. Studies valued between 7 and 198 total states, with 1-23 states valued per respondent. Different model specifications have been proposed for scoring. Some sample or demographic factors, including gender, education, percentage urban population, and national health care expenditure, were associated with differences in observed utilities for moderate or severe health states. CONCLUSIONS: . EQ-5D valuation studies conducted to date have varied widely in their design and in the resulting scoring algorithms. Therefore, we propose the Checklist for Reporting Valuation Studies of the EQ-5D (CREATE) for those conducting valuation studies.
Entities:
Keywords:
EQ-5D; health utility; reporting checklist; scoring algorithm; valuation
Authors: Szilárd Nemes; Kristina Burström; Niklas Zethraeus; Ted Eneqvist; Göran Garellick; Ola Rolfson Journal: Qual Life Res Date: 2015-06-03 Impact factor: 4.147
Authors: Lidia Engel; Duncan Mortimer; Stirling Bryan; Scott A Lear; David G T Whitehurst Journal: Pharmacoeconomics Date: 2017-07 Impact factor: 4.981
Authors: Fanni Rencz; László Gulácsi; Michael Drummond; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Elly A Stolk; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek Journal: Qual Life Res Date: 2016-07-29 Impact factor: 4.147
Authors: Feng Xie; Eleanor Pullenayegum; Kathy Gaebel; Nick Bansback; Stirling Bryan; Arto Ohinmaa; Lise Poissant; Jeffrey A Johnson Journal: Qual Life Res Date: 2016-02-13 Impact factor: 4.147